Recursion Pharmaceuticals, INC Form 4 insider transactions

Zavain Dar, a director at Recursion Pharmaceuticals, reported acquiring 1,467 shares of Class A Common Stock on April 1, 2024, and disclosed previously unreported shares received from a pro-rata distribution.

Director Terry-Ann Burrell acquired 1,467 shares of Recursion Pharmaceuticals' Class A Common Stock on April 1, 2024, under the company's Outside Director Compensation Policy.

Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock on April 2, 2024, under a pre-arranged 10b5-1 trading plan.

Christopher Gibson, CEO of Recursion Pharmaceuticals, reported the sale of 65,000 shares of Class A Common Stock and the conversion of 25,000 shares of Class B Common Stock into Class A Common Stock on March 28, 2024.

Tina Marriott, President and COO of Recursion Pharmaceuticals, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Director Blake Borgeson of Recursion Pharmaceuticals sold 20,054 shares of Class A Common Stock on March 19, 2024, under a pre-arranged 10b5-1 trading plan.

Chief Financial Officer of Recursion Pharmaceuticals, Michael Secora, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Christopher Gibson, CEO of Recursion Pharmaceuticals, reports multiple transactions involving Class A and Class B Common Stock, including acquisitions, disposals, and conversions, as part of a pre-arranged trading plan.

Blake Borgeson, a director at Recursion Pharmaceuticals, sold 20,054 shares of Class A Common Stock at an average price of $12.0577 per share on March 5, 2024, under a pre-arranged 10b5-1 trading plan.